CDK4/6 inhibitors block the G1 to S phase transition in cancer cells, and selective CDK4/6 inhibitors such as Palbociclib and Ribociclib have been approved by EMA and FDA for treating ER-negative metastatic BC [61,62]. This evidence concerns the gene CDK4 and breast cancer.